Skip to content
OpenCapital
Get started

Dianthus Therapeutics DNTH Quick ratio

Quick ratio at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
0.8×-0.3×
Amgen logo
AmgenAMGN
1×+0.1×
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
9×+0.9×
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
10.8×+2.3×
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
17.8×+0.5×
TG Therapeutics logo
TG TherapeuticsTGTX
5.7×+2.6×

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$4.51B+662%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0×0.0×
Current ratio29.3×+13.3×

Where this comes from

Calculated from Dianthus Therapeutics’s reported figures.

quick assets/total current liabilities=29.3×

Based on the most recent quarter.

The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dianthus Therapeutics's quick ratio?
Dianthus Therapeutics (DNTH) reported quick ratio of 29.3× in Q1 2026.
How has Dianthus Therapeutics's quick ratio changed year-over-year?
Dianthus Therapeutics's quick ratio increased by 83.0% year-over-year, from 16× to 29.3×.
What is the long-term trend for Dianthus Therapeutics's quick ratio?
Over 5 years (2020 to 2025), Dianthus Therapeutics's quick ratio has grown at a 0.1% compound annual growth rate (CAGR), from 13.3× to 13.3×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.